Clinicopathological correlation of insulin-like growth factor binding protein 3 and their death receptor in patients with gastric cancer

Amir Ansari , Ali Gheysarzadeh, Ali Sharifi, Mohammad Reza Mofid

Abstract


Background and purpose: The insulin-like growth factor binding protein 3 (IGFBP-3) and its novel death receptor (IGFBP-3R) have been exhibited to have tumor suppressor effects. Despite their prognostic value in some cancers, they have not been elucidated in gastric cancer.

Experimental approach: We collected 68 samples from patients with gastric cancer. IGFBP-3 and IGFBP-3R expression levels were evaluated with quantitative real-time polymerase chain reaction (RT-PCR) and western blotting in patients. The relationship between prognostic factors and IGFBP-3/IGFBP-3R expression was also evaluated.

Findings/Results: Our results showed that IGFBP-3 and IGFBP-3R expression was reduced significantly in tumor tissues. We found that there was an association between the reduction of IGFBP-3 with lymph node metastasis and tumor-node-metastasis (TNM) staging. Besides, IGFBP-3R expression was associated with tumor size, lymph node metastasis, differentiation, and TNM classification. Interestingly, we presented that the downregulation of IGFBP-3R was stage-dependent. In survival analysis, our findings showed that low levels of IGFBP-3R mRNA expression exhibited a close correlation with survival rate.

Conclusion and implications: The findings of this study showed that the expression levels of IGFBP-3 and IGFBP-3R are valuable prognostic factors. Despite the potential of IGFBP-3, IGFBP-3R plays a significant role as a prognostic factor in gastric cancer. However, these findings need to be developed and confirmed by further studies.


Keywords


Gastric cancer; IGFBP-3; IGFBP-3R; Prognostic factor; TNM classification.

Full Text:

PDF

References


Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020;21(11):4012,1-20. DOI: 10.3390/ijms21114012.

Chua YJ, Cunningham D. The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice. Ann Surg Oncol. 2007;14(10):2687-2690.DOI: 10.1245/s10434-007-9423-7.

Wagner AD, Syn NX, Moehler M, Grothe W, Yong WP, Tai BC, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8(8):CD004064,1-219. DOI: 10.1002/14651858.CD004064.pub4.

Abbas M, Habib M, Naveed M, Karthik K, Dhama K, Shi M, et al. The relevance of gastric cancer biomarkers in prognosis and pre-and post-chemotherapy in clinical practice. Biomed Pharmacother. 2017;95:1082-1090. DOI: 10.1016/j.biopha.2017.09.032.

Ranke MB. Insulin-like growth factor binding-protein-3 (IGFBP-3). Best Pract Res Clin Endocrinol. 2015;29(5):701-711. DOI: 10.1016/j.beem.2015.06.003.

Baxter RC. IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer. 2014;14(5):329-241. DOI: 10.1038/nrc3720.

Ranke MB. Insulin-like growth factor binding-protein-3 (IGFBP-3). Best Pract Res Clin Endocrinol. 2015;29(5):701-711. DOI: 10.1016/j.beem.2015.06.003.

Kim HS, Ingermann AR, Tsubaki J, Twigg SM, Walker GE, Oh Y. Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells. Cancer Res. 2004;64(6):2229-2237. DOI: 10.1158/0008-5472.can-03-1675.

Ingermann AR, Yang YF, Han J, Mikami A, Garza AE, Mohanraj L, et al. Identification of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate cancer. J Biol Chem. 2010;285(39):30233-30246. DOI: 10.1074/jbc.M110.122226.

Cai Q, Dozmorov M, Oh Y. IGFBP-3/IGFBP-3 receptor system as an anti-tumor and anti-metastatic signaling in cancer. Cells. 2020;9(5):1261,1-24. DOI: 10.3390/cells9051261.

Perks CM, Holly JM. Epigenetic regulation of insulin-like growth factor binding protein-3 (IGFBP-3) in cancer. J Cell Commun Signal. 2015;9(2):159-166. DOI: 10.1007/s12079-015-0294-6.

Gheysarzadeh A, Bakhtiari H, Ansari A, Emami Razavi A, Emami MH, Mofid MR. The insulin‐like growth factor binding protein‐3 and its death receptor in pancreatic ductal adenocarcinoma poor prognosis. J Cell Physiol. 2019;234(12):23537-23546. DOI: 10.1002/jcp.28922.

Hermanek P, Sobin LH, editor. TNM classification of malignant tumours. Berlin, Heidelberg: Springer; 2012. pp. 849-851. DOI: 10.1007/978-3-642-82982-6.

Gheysarzadeh A, Ansari A, Emami MH, Razavi AE, Mofid MR. Over-expression of low-density lipoprotein receptor-related protein-1 is associated with poor prognosis and invasion in pancreatic ductal adenocarcinoma. Pancreatology. 2019;19(3):429-435. DOI: 10.1016/j.pan.2019.02.012.

Kang C, Lee Y, Lee JE. Recent advances in mass spectrometry-based proteomics of gastric cancer. World J Gastroenterol. 2016;22(37):8283-8293. DOI: 0.3748/wjg.v22.i37.8283.

Lin LL, Huang HC, Juan HF. Discovery of biomarkers for gastric cancer: a proteomics approach. J Proteomics. 2012;75(11):3081-3097. DOI: 10.1016/j.jprot.2012.03.046.

Belczacka I, Latosinska A, Metzger J, Marx D, Vlahou A, Mischak H, et al. Proteomics biomarkers for solid tumors: current status and future prospects. Mass Spectrom Rev. 2019;38(1):49-78. DOI: 10.1002/mas.21572.

Hou YL, Luo P, Ji Gy, Chen H. Clinical significance of serum IGFBP-3 in colorectal cancer. J Clin Lab Anal. 2019;33(6):e22912,1-6. DOI: 10.1002/jcla.22912.

Yoneyama T, Ohtsuki S, Honda K, Kobayashi M, Iwasaki M, Uchida Y, et al. Identification of IGFBP2 and IGFBP3 as compensatory biomarkers for CA19-9 in early-stage pancreatic cancer using a combination of antibody-based and LC-MS/MS-based proteomics. PLoS One. 2016;11(8):e0161009,1-23. DOI: 10.1371/journal.pone.0161009.

Hur H, Yu EJ, Ham IH, Jin HJ, Lee D. Preoperative serum levels of insulin-like growth factor-binding protein 2 predict prognosis of gastric cancer patients. Oncotarget. 2017;8(7):10994-11003. DOI: 10.18632/oncotarget.14202.

Mofid MR, Gheysarzadeh A, Bakhtiyari S. Insulin-like growth factor binding protein 3 chemosensitizes pancreatic ductal adenocarcinoma through its death receptor. Pancreatology. 2020;20(7):1442-1450. DOI: 10.1016/j.pan.2020.07.406.

Yan J, Yang X, Li L, Liu P, Wu H, Liu Z, et al. Low expression levels of insulin-like growth factor binding protein-3 are correlated with poor prognosis for patients with hepatocellular carcinoma. Oncol Lett. 2017;13(5):3395-3402. DOI: 10.3892/ol.2017.5934.

Natsuizaka M, Kinugasa H, Kagawa S, Whelan KA, Naganuma S, Subramanian H, et al. IGFBP3 promotes esophageal cancer growth by suppressing oxidative stress in hypoxic tumor microenvironment. Am J Cancer Res. 2014;4(1):29-41. DOI: 2156-6976/ajcr0000245.

Kim ST, Jang HL, Lee J, Park SH, Park YS, Lim HY, et al. Clinical significance of IGFBP-3 methylation in patients with early stage gastric cancer. Transl Oncol. 2015;8(4):288-294. DOI: 10.1016/j.tranon.2015.06.001.

Zhang ZW, Newcomb PV, Moorghen M, Gupta J, Feakins R, Savage P, et al. Insulin-like growth factor binding protein-3: relationship to the development of gastric pre-malignancy and gastric adenocarcinoma (United Kingdom). Cancer Causes Control. 2004;15(2):211-218. DOI: 10.1023/B:CACO.0000019510.96285.e9.

Yi H, Hwang P, Yang DH, Kang CW, Lee DY. Expression of the insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs) in human gastric cancer cells. Eur J Cancer. 2001;37(17):2257-2263. DOI: 10.1016/s0959-8049(01)00269-6.

Marzec KA, Lin MZ, Martin JL, Baxter RC. Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage. Oncotarget. 2015;6(29):26583-26598. DOI: 10.18632/oncotarget.5612.

Baxter RC. Insulin-like growth factor binding protein-3 (IGFBP-3): novel ligands mediate unexpected functions. J Cell Commun Signal. 2013;7(3):179-189. DOI: 10.1007/s12079-013-0203-9.

Schedlich LJ, Le Page SL, Firth SM, Briggs LJ, Jans DA, Baxter RC. Nuclear import of insulin-like growth factor-binding protein-3 and-5 is mediated by the importin β subunit. J Biol Chem. 2000;275(31):23462-23470. DOI: 10.1074/jbc.M002208200.

Jafari E, Gheysarzadeh A, Mahnam K, Shahmohammadi R, Ansari A, Bakhtyari H, et al. In silico interaction of insulin-like growth factor binding protein 3 with insulin-like growth factor 1. Res Pharm Sci. 2018;13(4):332-342. DOI: 10.4103/1735-5362.235160.

Xue M, Fang Y, Sun G, Zhuo W, Zhong J, Qian C, et al. IGFBP3, a transcriptional target of homeobox D10, is correlated with the prognosis of gastric cancer. PLoS One. 2013;8(12):e81423,1-13. DOI: 10.1371/journal.pone.0081423.

Harada A, Jogie-Brahim S, Oh Y. Tobacco specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone suppresses a newly identified anti-tumor IGFBP-3/IGFBP-3R system in lung cancer cells. Lung Cancer. 2013;80(3):270-277. DOI: 10.1016/j.lungcan.2013.02.016.

Han J, Jogie-Brahim S, Harada A, Oh Y. Insulin-like growth factor-binding protein-3 suppresses tumor growth via activation of caspase-dependent apoptosis and cross-talk with NF-κB signaling. Cancer Lett. 2011;307(2):200-210. DOI: 10.1016/j.canlet.2011.04.004.

Lee YC, Jogie-Brahim S, Lee DY, Han J, Harada A, Murphy LJ, et al. Insulin-like growth factor-binding protein-3 (IGFBP-3) blocks the effects of asthma by negatively regulating NF-κB signaling through IGFBP-3R-mediated activation of caspases. J Biol Chem. 2011;286(20):17898-17909. DOI: 10.1074/jbc.M111.231035.

Sano A, Sangai T, Maeda H, Nakamura M, Hasebe T, Ochiai A. Kallikrein 11 expressed in human breast cancer cells releases insulin-like growth factor through degradation of IGFBP-3. Int J Oncol. 2007;30(6):1493-1498. PMID: 17487371.

Song G, Liu K, Zhu X, Yang X, Shen Y, Wang W, et al. The low IGFBP-3 level is associated with esophageal cancer patients: a meta-analysis. World J Surg Oncol. 2016;14(1):307,1-8. DOI: 10.1186/s12957-016-1055-6.

Torng P, Lee YC, Huang CY, Ye J, Lin Y, Chu Y, et al. Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma. Oncogene. 2008;27(15):2137-2147. DOI: 10.1038/sj.onc.1210864.

Santosh V, Arivazhagan A, Sreekanthreddy P, Srinivasan H, Thota B, Srividya MR, et al. Grade-specific expression of insulin-like growth factor-binding proteins-2,-3, and-5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma. Cancer Epidemiol Biomarkers Prev. 2010;19(6):1399-1408. DOI: 10.1158/1055-9965.EPI-09-1213.

Adachi Y, Nojima M, Mori M, Kubo T, Yamano Ho, Lin Y, et al. Circulating insulin‐like growth factor binding protein‐3 and risk of gastrointestinal malignant tumors. J Gastroenterol Hepatol. 2019;34(12):2104-2111. DOI: 10.1111/jgh.14753.

Gigek CO, Leal MF, Lisboa LCF, Silva PNO, Chen ES, Lima EM, et al. Insulin-like growth factor binding protein-3 gene methylation and protein expression in gastric adenocarcinoma. Growth Horm IGF Res. 2010;20(3):234-238. DOI: 10.1016/j.ghir.2010.02.005.

Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, et al. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and-3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol. 2002;20(3):833-841. DOI :10.1200/JCO.2002.20.3.833.

Wang Z, Wang Z, Liang Z, Liu J, Shi W, Bai P, et al. Expression and clinical significance of IGF-1, IGFBP-3, and IGFBP-7 in serum and lung cancer tissues from patients with non-small cell lung cancer. Onco Targets Ther. 2013;6:1437-1444. DOI: 10.2147/OTT.S51997.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.